All In Biotech

Drug Trial Radar · NCT05948774

A SAD/MAD Study to Evaluate the Safety, Tolerability, PK of MT200605 in Healthy Subjects

A Randomized, Double-blind, Placebo Control, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) of MT200605 for Injection in Healthy Subjects.

Last checked: Nov 19, 2026Latest source record: Nov 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

61

Actual

Start

Jul 11, 2023

Primary completion

Jan 22, 2024

Study completion Feb 11, 2024

Sponsor

Sponsor type
Industry
First posted
Jul 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this randomized, double-blind, placebo control, Phase I clinical trial is to evaluate the Safety, Tolerability, and Pharmacokinetics after Single Ascending Dose (SAD) and multiple Ascending Dose (MAD) of MT200605 for Injection in Healthy Subjects. The main questions it aims to answer are: 1. The safety and tolerability of MT200605 injection in health subjects 2. The Pharmacokinetic characteristic of MT200605 injction in health subjects The study aims to recruit 60 health subjects and participants will be randomly allocate to two stages (SAD and MAD) with 36 subjects in SAD and 24 subjects in MAD stages. The placebo will be used in this study, and the researchers will compare the placebo and test article to see if the MT200605 will be safe or well tolerated.

Conditions

  • Healthy

Interventions

  • MT200605 for InjectionDrug

    Two stages (SAD, MAD) were designed in this study. For SAD, the MT200605 will single Intravenous (IV) infusion for 1h with the dose level as 0.15 mg/kg、0.3 mg/kg、0.6 mg/kg、0.9 mg/kg、1.2 mg/kg. For MAD, the participants will IV infusion of the MT200605 for 7 days with 2 times per day under the dose level of 0.3 mg/kg、0.6 mg/kg、1.2 mg/kg. The dosing frequency will be Q12h. The drug/placebo in day 7 will be only administrated for 1 time on morning. The infusion duration will be 1h.

  • MT200605 PlaceboDrug

    Two stages (SAD, MAD) were designed in this study. For SAD, the MT200605 Placebo will single Intravenous (IV) infusion for 1h with the dose level as 0.15 mg/kg、0.3 mg/kg、0.6 mg/kg、0.9 mg/kg、1.2 mg/kg. For MAD, the participants will IV infusion of the MT200605 Placebo for 7 days with 2 times per day under the dose level of 0.3 mg/kg、0.6 mg/kg、1.2 mg/kg. The dosing frequency will be Q12h. The drug/placebo in day 7 will be only administrated for 1 time on morning. The infusion duration will be 1h.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events(AEs)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks.
  2. Adverse Events(AEs)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks.
  3. Vital signs (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks.
  4. Vital signs (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks.
  5. Vital signs (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  6. Vital signs (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  7. Vital signs (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  8. Vital signs (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  9. Vital signs (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  10. Vital signs (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  11. 12-lead electrocardiogram (ECG) recordings (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  12. 12-lead electrocardiogram (ECG) recordings (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  13. 12-lead electrocardiogram (ECG) recordings (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  14. 12-lead electrocardiogram (ECG) recordings (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  15. 12-lead electrocardiogram (ECG) recordings (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  16. 12-lead electrocardiogram (ECG) recordings (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  17. 12-lead electrocardiogram (ECG) recordings (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  18. 12-lead electrocardiogram (ECG) recordings (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  19. 12-lead electrocardiogram (ECG) recordings (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  20. 12-lead electrocardiogram (ECG) recordings (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  21. Physical examinations-Head (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  22. Physical examinations-Eyes (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  23. Physical examinations-Ears (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  24. Physical examinations-Nose (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  25. Physical examinations-throat (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  26. Physical examinations-neck (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  27. Physical examinations-lung (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  28. Physical examinations-Abdomen (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  29. Physical examinations-skin (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  30. Physical examinations-Musculoskeletal (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  31. Physical examinations-Cardiovascular (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  32. Physical examinations-neurological (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  33. Physical examinations-lung (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  34. Physical examinations-Abdomen (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  35. Physical examinations-skin (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  36. Physical examinations-Cardiovascular (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  37. Clinical laboratory test-hematology (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  38. Clinical laboratory test-hematology (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  39. Clinical laboratory test-hematology (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  40. Clinical laboratory test-biochemistry (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  41. Clinical laboratory test-biochemistry (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  42. Clinical laboratory test-Urinalysis (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  43. Clinical laboratory test-Coagulation (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  44. Clinical laboratory test-Coagulation (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  45. Clinical laboratory test-Coagulation (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  46. Clinical laboratory test-Cardiac Enzymes (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  47. Clinical laboratory test-Cardiac Enzymes (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  48. Clinical laboratory test-hematology (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  49. Clinical laboratory test-hematology (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  50. Clinical laboratory test-hematology (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  51. Clinical laboratory test-biochemistry (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  52. Clinical laboratory test-biochemistry (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  53. Clinical laboratory test-Urinalysis (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  54. Clinical laboratory test-Coagulation (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  55. Clinical laboratory test-Coagulation (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  56. Clinical laboratory test-Coagulation (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  57. Clinical laboratory test-Cardiac Enzymes (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
  58. Clinical laboratory test-Cardiac Enzymes (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.